This study clearly showed that Doxil® (as compared to doxorubicin (Adriamycin)) reduced the incidence of cardiotoxicity in women with breast cancer without compromising outcomes. Thus Doxil® could be included in standard multi-drug regimens for the treatment of breast cancer. Doxil is one of several new "liposomal" chemotherapy drugs.